Generic Synribo Availability

Synribo is a brand name of omacetaxine, approved by the FDA in the following formulation(s):

SYNRIBO (omacetaxine mepesuccinate - powder;subcutaneous)

• Manufacturer: TEVA PHARMS INTL
  Approval date: October 26, 2012
  Strength(s): 3.5MG/VIAL ^[RLD]

Has a generic version of Synribo been approved?

No. There is currently no therapeutically equivalent version of Synribo available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Synribo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents
  Patent 6,987,103
  Issued: January 17, 2006
  Inventor(s): Robin; Jean-Pierre & Mahon; François-Xavier & Maisonneuve; Hervé & Maloisel; Frederick & Blanchard; Julie
  Assignee(s): Stragen Pharma S.A.
  

  The present invention concerns a method of treating chronic myelogenous leukemia, a related myeloproliferative disorder or a Ph-positive acute lymphocytic leukemia in a subject animal, comprising: (a) selecting or identifying an animal suffering from chronic myelogenous leukemia or a related myeloproliferative disorder and showing resistance or intolerance to treatment with STI571; and (b) administering to the animal homoharringtonine. In a preferred embodiment, the animal is a human being.

  Patent expiration dates:

  • October 26, 2026
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)
• Cephalotaxane derivatives and their processes of preparation and purification
  Patent RE45128
  Issued: September 9, 2014
  Assignee(s): IVAX International GmbH
  

  The present invention concerns a new general process for asymmetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. This process comprises direct esterification of a natural cephalotaxine with an acylating compound constituted of a side chain precursor which backbone and functionalization are entirely preformed. The invention also concerns a natural, synthetic or semi-synthetic harringtonines including their tautomeric forms and their salts of the following formula: wherein n=2 (i.e. harringtonine) or n=3 (i.e. homoharringtonine), in which the total content of impurities, possibly including enantiomeric forms, is lower than 1%, and/or the content of the major impurity is lower than 0.9%, and/or the chromatographic assay exhibits a harringtonines content higher than 97.5%.

  Patent expiration dates:

  • March 16, 2019
    
    ✓ 
    Patent use: TREATMENT OF LEUKEMIA
    ✓ 
    Drug substance
    ✓ 
    Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:

  • October 26, 2019 - TREATMENT OF ADULT PATIENTS WITH CHRONIC OR ACCELERATED PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE AND/OR INTOLERANCE TO TWO OR MORE TYROSINE KINASE INHIBITORS (TKI)